Literature DB >> 31851430

Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: Is interpretation affected by type of fixation?

John R Gosney1, Alexander Haragan2, Claire Chadwick1, Tom E Giles1, Seamus Grundy3, Victoria Tippett4, Krishna P Gumparthy5,6, Andrew Wight5,6, Hock G Tan5,6.   

Abstract

BACKGROUND: Much of the reluctance about using cytology specimens rather than histology specimens to assess programmed death ligand 1 (PD-L1) expression for guiding the use of immune modulating drugs in the management of non-small cell lung cancer (NSCLC) is based on the belief that the alcohol-based fixatives favored by cytopathologists might reduce the antigenicity of PD-L1 and lead to artifactually low expression levels and false-negative reporting. Therefore, this study was performed to determine whether there is any difference in PD-L1 expression between endobronchial ultrasound (EBUS)-guided aspirates of NSCLC fixed in alcohol-based fixatives and those fixed in neutral buffered formalin (NBF), the standard laboratory fixative for histology specimens.
METHODS: The expression of PD-L1 was compared in 50 paired EBUS aspirates of NSCLC taken from the same lymph node during the same procedure. One aspirate of each pair was fixed in an alcohol-based fixative, and the other was fixed in NBF.
RESULTS: In none of the 50 pairs was there any significant difference, qualitative or quantitative, in the strength, pattern, or extent of PD-L1 expression. In the great majority, the expression was identical, regardless of fixation.
CONCLUSIONS: There is no evidence from this study showing that the use of alcohol-based fixatives has any effect on the expression of PD-L1 or its interpretation. Notwithstanding the general challenges in accurately assessing such expression in cytology specimens, pathologists should feel able to interpret them with confidence, and clinicians should feel able to rely on the results.
© 2019 American Cancer Society.

Entities:  

Keywords:  cytology; fixation; immunochemistry; lung cancer; programmed death ligand 1 (PD-L1)

Mesh:

Substances:

Year:  2019        PMID: 31851430     DOI: 10.1002/cncy.22216

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  7 in total

1.  Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.

Authors:  Si Kei Lou; Hyang Mi Ko; Tomonari Kinoshita; Scott MacDonald; Jessica Weiss; Katarzyna Czarnecka-Kujawa; Scott L Boerner; Kazuhiro Yasufuku; Ming-Sound Tsao; Joerg Schwock
Journal:  Acta Cytol       Date:  2020-06-29       Impact factor: 2.319

Review 2.  Linear Endobronchial Ultrasound in the Era of Personalized Lung Cancer Diagnostics-A Technical Review.

Authors:  Filiz Oezkan; Stephan Eisenmann; Kaid Darwiche; Asmae Gassa; David P Carbone; Robert E Merritt; Peter J Kneuertz
Journal:  J Clin Med       Date:  2021-11-30       Impact factor: 4.241

Review 3.  Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.

Authors:  Swati Satturwar; Ilaria Girolami; Enrico Munari; Francesco Ciompi; Albino Eccher; Liron Pantanowitz
Journal:  Diagn Cytopathol       Date:  2022-03-16       Impact factor: 1.390

Review 4.  PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.

Authors:  Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström
Journal:  Acta Cytol       Date:  2021-07-07       Impact factor: 2.319

5.  Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.

Authors:  Bregje M Koomen; Jose van der Starre-Gaal; Judith M Vonk; Jan H von der Thüsen; Jacqueline J C van der Meij; Kim Monkhorst; Stefan M Willems; Wim Timens; Nils A 't Hart
Journal:  Cancer Cytopathol       Date:  2020-10-27       Impact factor: 5.284

Review 6.  PD-L1 and beyond: Immuno-oncology in cytopathology.

Authors:  Antonino Iaccarino; Maria Salatiello; Ilaria Migliatico; Caterina De Luca; Gianluca Gragnano; Maria Russo; Claudio Bellevicine; Umberto Malapelle; Giancarlo Troncone; Elena Vigliar
Journal:  Cytopathology       Date:  2021-05-06       Impact factor: 2.073

7.  False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.

Authors:  Bregje M Koomen; Willem Vreuls; Mirthe de Boer; Emma J de Ruiter; Juergen Hoelters; Aryan Vink; Stefan M Willems
Journal:  Histopathology       Date:  2021-06-08       Impact factor: 5.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.